Search Results

• • 126 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

  1

  Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

  Authors:Luis A Diaz, Jr., Kai-Keen Shiu, Tae-Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, et al.From:Lancet Oncology (Vol. 23, Issue 5) Peer-Reviewed

  May 2022909 words Article

   Abstract Only
• Select Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.

  2

  Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.

  Authors:Mashiro Okunaka, Daisuke Kotani, Ken Demachi, Hisashi Fujiwara, Shingo Sakashita, Takayuki Yoshino, et al.From:Esophagus (Vol. 19, Issue 2) Peer-Reviewed

  Apr. 2022312 words Report, Brief articl...

   Abstract Only
• Select DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy.

  3

  DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy.

  Authors:Masaaki Miyo, Takeshi Kato, Yoshiaki Nakamura, Hiroya Taniguchi, Yusuke Takahashi, Masayuki Ishii, et al.From:Cancer Science (Vol. 113, Issue 4) Peer-Reviewed

  Apr. 2022282 words Report, Brief articl...

   Abstract Only
• Select Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer [greater than or equal to] 70 years.

  4

  Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer [greater than or equal to] 70 years.

  Authors:Demetris Papamichael, Guilherme S. Lopes, Curt L. Olswold, Jean-Yves Douillard, Richard A. Adams, Timothy S. Maughan, et al.From:European Journal of Cancer (Vol. 163) Peer-Reviewed

  Mar. 2022714 words Report

   Abstract Only
• Select Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer.

  5

  Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer.

  Authors:Hideaki Bando, Yuichiro Tsukada, Masaaki Ito, and Takayuki YoshinoFrom:Clinical Colorectal Cancer (Vol. 21, Issue 1) Peer-Reviewed

  Mar. 2022408 words Report, Author abstr...

   Abstract Only
• Select Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a firstâline treatment for metastatic colorectal cancer: Safety leadâin results from the QUATTRO-II study.

  6

  Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a firstâline treatment for metastatic colorectal cancer: Safety leadâin results from the QUATTRO-II study.

  Authors:Daisuke Kotani, Takayuki Yoshino, Masahito Kotaka, Akihito Kawazoe, Toshiki Masuishi, Hiroya Taniguchi, et al.From:Investigational New Drugs (Vol. 39, Issue 6) Peer-Reviewed

  Dec. 2021400 words Clinical report

   Abstract Only
• Select The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.

  7

  The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.

  Authors:Yutaka Hatanaka, Takeshi Kuwata, Eiichi Morii, Yae Kanai, Hitoshi Ichikawa, Takashi Kubo, et al.From:Pathology International (Vol. 71, Issue 11) Peer-Reviewed

  Nov. 2021299 words Report, Brief articl...

   Abstract Only
• Select SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.

  8

  SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.

  Authors:Yoshiaki Nakamura, Takao Fujisawa, Hiroya Taniguchi, Hideaki Bando, Wataru Okamoto, Katsuya Tsuchihara, et al.From:Cancer Science (Vol. 112, Issue 11) Peer-Reviewed

  Nov. 2021207 words Report, Brief articl...

   Abstract Only
• Select BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.

  9

  BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.

  Authors:Shin Kobayashi, Shinichiro Takahashi, Shogo Nomura, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, et al.From:Cancer Medicine (Vol. 10, Issue 20) Peer-Reviewed

  Oct. 2021292 words Report, Brief articl...

   Abstract Only
• Select COLOMATE challenge to overcome resistance in metastatic colorectal cancer.

  10

  COLOMATE challenge to overcome resistance in metastatic colorectal cancer.

  Author:Takayuki YoshinoFrom:Oncology (Vol. 35, Issue 10) Peer-Reviewed

  Oct. 2021690 words Article 1630LMost patients with metastatic colorectal cancer (mCRC) who receive palliative systemic therapy eventually develop resistance to treatment. Understanding the mechanisms by which malignant cells evade treatment could open...
• Select Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

  11

  Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

  Authors:Toshihiko Doi, Takayuki Yoshino, Nozomu Fuse, Narikazu Boku, Kentaro Yamazaki, Wasaburo Koizumi, et al.From:Investigational New Drugs (Vol. 33, Issue 5) Peer-Reviewed

  Oct. 2015395 words Author abstract

   Abstract Only
• Select Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

  12

  Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

  Authors:Daisuke Kotani, Kohei Shitara, Akihito Kawazoe, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, et al.From:Clinical Colorectal Cancer (Vol. 15, Issue 3) Peer-Reviewed

  Sept. 2016145 words Author abstract, Rep...

   Abstract Only
• Select Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience

  13

  Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience

  Authors:Akihito Kawazoe, Kohei Shitara, Shota Fukuoka, Masaaki Noguchi, Yasutoshi Kuboki, Hideaki Bando, et al.From:Investigational New Drugs (Vol. 33, Issue 3) Peer-Reviewed

  June 2015331 words Author abstract

   Abstract Only
• Select Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

  14

  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

  Authors:Toshiaki Watanabe, Kei Muro, Yoichi Ajioka, Yojiro Hashiguchi, Yoshinori Ito, Yutaka Saito, et al.From:International Journal of Clinical Oncology (Vol. 23, Issue 1) Peer-Reviewed

  Feb. 2018998 words Report

   Abstract Only
• Select Systemic transduction of [p16.sup.INK4a] antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice

  15

  Systemic transduction of [p16.sup.INK4a] antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice

  Authors:Toru Shimazui, Kazuhiro Yoshikawa, Ryutaro Ishitsuka, Takahiro Kojima, Shuya Kandori, Takayuki Yoshino, et al.From:Oncology Letters (Vol. 17, Issue 1) Peer-Reviewed

  Jan. 20194,386 words Report 1480L[p16.sup.INK4a] (p16) is a key molecule in bladder tumor (BT) development. We previously reported that a p16 antitumor peptide inhibited the growth of subcutaneous BT grafts in mice through restoration of p16 function...
• Select Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.

  16

  Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.

  Authors:Bengt Glimelius, Sebastian Stintzing, John Marshall, Takayuki Yoshino, and Aimery de GramontFrom:Cancer Treatment Reviews (Vol. 98) Peer-Reviewed

  July 2021400 words Report, Brief articl...

   Abstract Only
• Select Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples

  17

  Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples

  Authors:Masahiro Kurobe, Takahiro Kojima, Kouichi Nishimura, Shuya Kandori, Takashi Kawahara, Takayuki Yoshino, et al.From:PLoS ONE (Vol. 11, Issue 12) Peer-Reviewed

  Dec. 8, 20167,677 words Report 1380LIntroduction and Objectives Oncogenic FGFR3-TACC3 fusions and FGFR3 mutations are target candidates for small molecule inhibitors in bladder cancer (BC). Because FGFR3 and TACC3 genes are located very closely on...
• Select Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer

  18

  Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer

  Authors:Koichi Taira, Narikazu Boku, Akira Fukutomi, Yusuke Onozawa, Shuichi Hironaka, Takayuki Yoshino, et al.From:Journal of Gastroenterology (Vol. 43, Issue 11) Peer-Reviewed

  Nov. 2008342 words Report

   Abstract Only
• Select Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients

  19

  Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients

  Authors:Nozomu Fuse, Emiko Nagahisa-Oku, Toshihiko Doi, Takahide Sasaki, Shogo Nomura, Takashi Kojima, et al.From:Gastric Cancer (Vol. 16, Issue 3) Peer-Reviewed

  July 2013374 words Report

   Abstract Only
• Select Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel

  20

  Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel

  Authors:Masaki Matsuoka, Narikazu Boku, Takayuki Yoshino, Shuichi Hironaka, Yusuke Onozawa, Akira Fukutomi, et al.From:International Journal of Clinical Oncology (Vol. 10, Issue 6) Peer-Reviewed

  Dec. 2005300 words Author abstract 60L

   Abstract Only